XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q3)Nov 30, 2024 | (Q2)Aug 31, 2024 | (Q1)May 31, 2024 | (FY)Feb 29, 2024 | (Q4)Feb 29, 2024 | (Q3)Nov 30, 2023 | (Q2)Aug 31, 2023 | (Q1)May 31, 2023 | (FY)Feb 28, 2023 | (Q4)Feb 28, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -88.87%8.32M | 21.59%44.6M | -79.08%25.32M | 46.98%306.07M | -53.62%73.61M | -40.21%74.73M | 199.06%36.68M | 415.02%121.06M | 47.87%208.24M | 8.80%158.72M |
Net income from continuing operations | -34.63%49.62M | -37.86%17.01M | -72.53%6.2M | 17.67%168.59M | 18.11%42.73M | 46.45%75.9M | -10.73%27.38M | -8.19%22.58M | -35.97%143.27M | -9.08%36.18M |
Operating gains losses | 100.06%19K | --0 | 88.21%-29K | -2,565.67%-33.93M | 903.45%582K | -137,180.00%-34.27M | --0 | 81.59%-246K | 53.81%-1.27M | 87.10%58K |
Depreciation and amortization | 6.36%13.22M | -0.71%13.79M | 29.13%13.84M | 15.25%51.5M | 27.38%14.46M | 6.13%12.43M | 24.93%13.89M | 2.07%10.72M | 24.71%44.68M | 16.48%11.35M |
Deferred tax | -109.70%-639K | -147.69%-1.41M | 168.03%10.45M | 689.21%13.21M | 94.09%-220K | 363.61%6.59M | -12.34%2.95M | 534.69%3.9M | 74.73%-2.24M | -2,380.67%-3.72M |
Other non cash items | -21.57%3.06M | 71.74%3.28M | 20.82%3.2M | 22.02%13.2M | 92.13%4.74M | 47.17%3.9M | -34.15%1.91M | -5.36%2.65M | 2.37%10.82M | -15.49%2.47M |
Change In working capital | -40,866.44%-61.04M | 137.74%6.4M | -120.72%-14.25M | 443.86%53.53M | -98.41%1.86M | -100.28%-149K | 81.80%-16.97M | 174.33%68.78M | 89.80%-15.57M | 34.40%117.26M |
-Change in receivables | -20.50%-88.15M | 7.06%-38.26M | 141.63%64.6M | -122.32%-18.67M | -46.72%68.91M | -7,133.46%-73.15M | -28.16%-41.16M | 282.61%26.73M | 225.12%83.62M | 78.50%129.34M |
-Change in inventory | 95.60%18.89M | -1,307.01%-24.88M | -326.01%-48.75M | -47.24%58.19M | -64.66%28.73M | -90.92%9.66M | 94.02%-1.77M | 145.15%21.57M | 340.25%110.3M | 40.41%81.31M |
-Change in prepaid assets | -3,257.76%-3.9M | 43.59%-2.24M | -151.06%-3.57M | -186.57%-2.41M | 370.21%3.1M | -103.46%-116K | -5,125.00%-3.97M | -318.13%-1.42M | 149.70%2.78M | -197.62%-1.15M |
-Change in payables and accrued expense | -81.17%12.1M | 145.66%72.54M | -219.11%-26.86M | 109.08%19.24M | -4.45%-97.13M | 209.42%64.29M | 197.71%29.53M | 175.31%22.55M | -664.82%-211.92M | -112.28%-93M |
-Change in other working capital | 101.57%13K | -290.57%-768K | 149.85%327K | -697.18%-2.83M | -330.61%-1.75M | -189.43%-829K | 133.11%403K | 20.29%-656K | 94.62%-355K | 256.29%758K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -88.87%8.32M | 21.59%44.6M | -79.08%25.32M | 46.98%306.07M | -53.62%73.61M | -40.21%74.73M | 199.06%36.68M | 415.02%121.06M | 47.87%208.24M | 8.80%158.72M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -127.61%-9.48M | 43.09%-4.94M | 21.24%-9.16M | 101.71%5.45M | 70.13%-8.56M | 208.11%34.32M | 76.16%-8.68M | 94.77%-11.63M | 27.24%-319.33M | 93.59%-28.66M |
Capital expenditure reported | 10.91%-8.13M | 43.73%-4.88M | 23.03%-9.14M | 79.04%-36.64M | 75.71%-6.96M | 72.81%-9.12M | 76.18%-8.68M | 84.41%-11.88M | -124.07%-174.86M | 21.47%-28.67M |
Net PPE purchase and sale | -92.22%106K | --1K | -84.55%38K | 2,247.83%1.62M | 83.33%11K | 3,069.77%1.36M | --0 | --246K | -98.70%69K | --6K |
Net business purchase and sale | ---- | ---- | ---- | 134.22%49.46M | --0 | ---- | ---- | ---- | 60.53%-144.54M | --0 |
Net investment purchase and sale | 80.27%-1.46M | ---57K | ---57K | ---8.98M | ---1.61M | ---7.37M | --0 | --0 | --0 | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -127.61%-9.48M | 43.09%-4.94M | 21.24%-9.16M | 101.71%5.45M | 70.13%-8.56M | 208.11%34.32M | 76.16%-8.68M | 94.77%-11.63M | 27.24%-319.33M | 93.59%-28.66M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 120.21%21.83M | 16.37%-35.67M | 81.42%-18.51M | -401.63%-322.09M | 50.93%-71.79M | -23.39%-108.02M | -166.82%-42.65M | -135.99%-99.63M | -62.71%106.78M | -150.36%-146.32M |
Net issuance payments of debt | 118.56%20.34M | -576.77%-35.46M | 184.44%82.39M | -322.99%-269.08M | 52.59%-69.39M | -22.33%-109.56M | -88.47%7.44M | -133.40%-97.56M | -74.25%120.67M | -140.05%-146.37M |
Net common stock issuance | 90.20%-30K | 99.78%-109K | -2,217.48%-103.04M | -200.69%-55.22M | -2,440.00%-381K | -580.00%-306K | -61,738.27%-50.09M | 75.60%-4.45M | 90.24%-18.37M | 99.98%-15K |
Proceeds from stock option exercised by employees | -17.82%1.52M | --0 | -0.92%2.36M | -16.40%4.24M | -95.45%3K | -10.36%1.85M | --0 | -18.88%2.38M | -14.94%5.07M | -71.91%66K |
Net other financing activities | ---- | ---- | ---222K | -245.56%-2.03M | ---- | ---- | ---- | ---- | ---586K | --0 |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 120.21%21.83M | 16.37%-35.67M | 81.42%-18.51M | -401.63%-322.09M | 50.93%-71.79M | -23.39%-108.02M | -166.82%-42.65M | -135.99%-99.63M | -62.71%106.78M | -150.36%-146.32M |
Net cash flow | ||||||||||
Beginning cash position | -16.84%20.14M | -58.46%16.15M | -36.36%18.5M | -12.91%29.07M | -44.31%25.25M | -38.93%24.21M | -21.08%38.87M | -12.91%29.07M | -26.02%33.38M | 2.24%45.34M |
Current changes in cash | 1,900.68%20.67M | 127.22%3.99M | -124.02%-2.35M | ---- | ---- | -81.84%1.03M | -52.59%-14.66M | -38.29%9.8M | ---- | ---- |
End cash Position | 61.62%40.8M | -16.84%20.14M | -58.46%16.15M | ---- | ---- | -44.31%25.25M | -38.93%24.21M | -21.08%38.87M | ---- | ---- |
Free cash flow | -99.71%191K | 41.85%39.71M | -85.18%16.18M | 707.19%269.42M | -48.75%66.65M | -28.24%65.6M | 138.11%28M | 195.24%109.18M | -46.84%33.38M | 18.91%130.05M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |